Collectively, these findings indicate a strategy of combined treatment with MerTK and NF-κB inhibitors could be effective for reducing tumor cell proliferation, potentially by altering the composition of immune/inflammatory cells in the tumor microenvironment. Here, MERTK is linked to neoplasm.